Between September 1994 and October 1995, we diagnosed and treated four cases of early onset posttransplantation lymphoproliferative disorder (PTLD) occurring within 62 days of pancreas transplantation. The development of PTLD was associated with both a significantly higher total muromonab-CD3 (OKT3) dose and a lack of ganciclovir/acyclovir prophylaxis, but it was not associated with the total dose of antithymocyte globulin or cytomegalovirus serostatus. All four patients were treated aggressively and survived without evidence of recurrent PTLD more than 1.5 years later. We conclude that the use of a high total dose of OKT3 puts pancreas transplant recipients at increased risk for early onset PTLD, while ganciclovir/acyclovir prophylaxis may help to prevent this disorder; however, if early onset PTLD does occur in these patients, aggressive therapy can lead to a favorable outcome.
Posttransplantation lymphoproliferative disorder (PTLD) reMethods sults from Epstein-Barr virus (EBV) -associated proliferation

Patient Population
of B lymphocytes in the immunosuppressed host [1, 2] . The spectrum of disease associated with PTLD ranges from relaOne hundred and four simultaneous pancreas and kidney tively benign polyclonal plasmacytic hyperplasia to malignant transplantations and six pancreas transplantations alone were immunoblastic lymphoma or multiple myeloma [1 -3] .
performed at the University of Maryland Hospital (Baltimore) The incidence of PTLD in solid organ transplant recipients between 1 July 1991 and 1 October 1995. All four cases of appears to depend upon both the type of organ transplanted PTLD occurred among 56 patients who received transplants and the immunosuppressive regimen used. While the observed since the initiation of a protocol using antithymocyte globulin incidence of PTLD is in the range of 1% for renal transplant induction with OKT3 treatment for early rejection, begun 1 recipients, it can be as high as 9% for heart/lung transplant January 1994. Forty-nine of these 56 patients were evaluable recipients and 12% for pancreas transplant recipients [4 -6] .
for risk factors associated with the development of PTLD; the Moreover, the incidence of PTLD has been shown to increase 7 patients who were excluded from analysis included 1 who significantly following the administration of antithymocyte received only a pancreas transplant and lost his graft because agents including muromonab-CD3 (OKT3) to cardiac transof thrombosis within 24 hours of transplantation and 6 who plantation patients or administration of OKT3 and antilymphodid not have documented EBV infection (as determined by cyte globulin to kidney transplant recipients [7, 8] .
seropositivity of the donor or recipient). The underlying disease We similarly noted a dramatic increase in the incidence of in each of the 49 evaluable patients was insulin-dependent PTLD in pancreas transplant recipients at our center following diabetes mellitus. the initiation of a protocol that included antithymocyte globulin (Atgam; Upjohn Pharmaceuticals, Kalamazoo, MI) for inducImmunosuppressive Regimens tion immunosuppression and OKT3 treatment for early rejection. This PTLD differed from classic PTLD in that it occurred After 1 January 1994, all patients received antithymocyte in EBV-seropositive recipients within 62 days following transglobulin for induction immunosuppression at an initial dosage plantation (early onset PTLD). The correlation of development of 15 mg/kg q.d. for 4 -15 days; in specific cases, this dosage of PTLD with total dose of either agent was therefore analyzed.
was adjusted upward to 30 mg/kg q.d. on the basis of the total CD3 cell count. Thirty-six (73.5%) of the 49 evaluable patients also received OKT3 either for early rejection or to complete induction immunosuppression if therapeutic CD3 levels were 597 CID 1998; 26 (March) PTLD in Pancreas Recipients
Statistical Analysis
All patients also received azathioprine (2.5 -3.0 mg/kg iv preoperatively, followed by 1 mg/kg q.d. iv until oral medicaFactors considered for their possible association with the tion was possible, and then 2 mg/kg q. cance. Pancreas transplantation patients at known risk for cytomegalovirus (CMV) disease (i.e., the recipient, donor, or both were seropositive for CMV) routinely received antiviral prophylaxis Results for a total of 6 months post-transplantation. The group consid-
Development of PTLD Associated with Immunosuppressive
ered to be at highest risk (8 CMV-seronegative recipients of Regimen organs from CMV-seropositive donors) received ganciclovir (5 mg/kg b.i.d. for 10 -14 days, followed by 5 mg/kg q.d. for
Four of the 49 patients developed PTLD an average of 45 days (range, 34 -62 days) after transplantation, for an overall 14 days) and then acyclovir (800 mg po t.i.d.) for a total of 6 months of therapy; this group also received intravenous immuincidence of 8.2%. Three of the 4 had received simultaneous pancreas and kidney allografts (as compared with 46 of the 49 noglobulin every other week for the first 8 weeks. CMVseropositive recipients received ganciclovir (5 mg/kg b.i.d. for total patients), while 1 received only a pancreas transplant (as compared with 3 of the 49 total patients). The patients who 10 -14 days and then 5 mg/kg q.d. for up to 14 days) followed by acyclovir (800 mg po t.i.d.), for a total of 6 months of developed PTLD were similar to patients who did not develop PTLD with respect to age, race, and gender (table 1) . Similarly, therapy. However, ganciclovir therapy was terminated and acyclovir therapy was begun for the seropositive patients upon all four patients who developed PTLD and all 45 patients who did not were EBV-seropositive before transplantation, thus discharge from the hospital, so that few of them received ú14 days of ganciclovir therapy initially. In addition, all patients at eliminating recipient EBV serostatus as a parameter for risk factor analysis. risk for CMV disease resumed high-dose ganciclovir therapy at the time antirejection therapy was begun; the total amount Analysis of the total cumulative dose of OKT3 received within the first 2 months post-transplantation (and prior to of ganciclovir received by these patients therefore varied greatly, with all patients at risk for CMV disease receiving an development of PTLD) indicated that EBV-seropositive recipients with PTLD had received significantly higher total doses average total of 28.4 { 7.3 days (range, 8 -62 days) of ganciclovir therapy during their initial hospitalization.
of OKT3 (mean, 95.0 { 33.0 mg; range, 45 -130 mg) than patients who did not develop PTLD (mean, 45.4 { 38.0 mg; Patients who were CMV-seronegative recipients of organs from CMV-seronegative donors were all seropositive for herrange, 0 -125 mg) (Wilcoxon's rank-sum test, P õ .001) ( figure  1 and table 1 ). The higher cumulative dose of OKT3 was given pes simplex virus before transplantation, and were therefore given a lower dose of acyclovir alone (200 mg po t.i.d) for 6 because of rejection in each case. In comparison, the total dose of antithymocyte globulin was months. similar between the two groups (mean of 210.9 { 111.4 mg/kg and range of 50 -540 mg/kg for patients who developed
Pathological Studies
PTLD, vs. mean of 228.8 { 196.7 mg/kg and range of 20 -540 mg/kg for patients who did not develop PTLD; P Å .78). Hematoxylin and eosin -stained histologic sections were prepared from fixed, paraffin-embedded sections. Each case of One of the 4 patients with PTLD had received cyclosporin A (as compared with 42 of the 49 patients), while 3 had received PTLD was confirmed by biopsy of lymph nodes or other involved organs. Immunohistochemical staining, including stain-FK506 (as compared with 19 of the 49 patients; some patients received both agents); however, possibly because of the small ing for the latent membrane protein-1 of EBV, and in situ hybridization for EBV-encoded (EBER) RNA of EBV were number of patients involved, no significant difference in risk for PTLD was associated specifically with FK506 (two-tailed performed on fixed paraffin-embedded sections. Lesions were classified according to the scheme of Knowles et al. [2] .
Fisher's exact test, P Å .28).
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Development of PTLD Associated with Lack of Prophylaxis
for rejection or the development of PTLD); all other patients with Ganciclovir/High-Dose Acyclovir received low-dose oral acyclovir for 6 months (or until treatment for rejection or the development of PTLD). The developThree of the four patients who developed PTLD were CMVment of PTLD overall was significantly correlated with a lack seronegative recipients of organs from CMV-seronegative doof prophylaxis with ganciclovir/high-dose acyclovir (two-tailed nors (CMV 0/0); these three patients had not received the Fisher's exact test, P Å .036), while CMV seronegativity for ganciclovir/high-dose acyclovir prophylaxis given to CMV both donor and recipient approached but did not achieve a //0, ///, and 0// patients but were receiving low-dose significant correlation (P Å .08) (table 1) Because four of the 13 CMV 0/0 patients had nonetheless Eleven of our 49 patients received high-dose OKT3 (defined as ú75 mg), which has been associated with development of received ganciclovir prophylaxis during both induction and OKT3 treatment of early rejection, we were able to analyze PTLD in heart transplant recipients [7] . Three of the 11 patients who received high-dose OKT3 developed PTLD, and therefore the possible association of CMV serostatus or use of ganciclovir/high-dose acyclovir prophylaxis with development of the use of high-dose OKT3 alone increased the risk of PTLD from 8.2% overall to 27.3%. Similarly, three of nine patients PTLD. All patients given ganciclovir/high-dose acyclovir prophylaxis initially received 6 -28 days of ganciclovir, followed who did not receive ganciclovir/acyclovir prophylaxis developed PTLD, increasing the risk of PTLD to 33%. by high-dose oral acyclovir for 5 -6 months (or until treatment / 9c48$$mr24 02-05-98 21:41:37 cida UC: CID lymph nodes in the other). Immunosuppression was discontinued, and the kidney and pancreas allografts were removed from both patients (numbers 1 and 2), who were also treated with high-dose intravenous acyclovir and intravenous gammaglobulin; IFN a therapy was added for the patient with more extensive organ involvement (patient 3). Both of these patients also remained disease-free ú1.5 year following the diagnosis of PTLD. Patient 4, who received a pancreas transplant alone, had monomorphic B cell PTLD that would be classified as malignant lymphoma, large-cell immunoblastic type. The atypical cells invaded the pancreas, liver, and bone marrow, and there was extensive necrosis in the pancreas. Her immunosuppression was also discontinued, her allograft was removed, and treatment with chemotherapeutic agents was given. Almost 2 years have passed since the diagnosis of her PTLD, and she With the use of more potent immunosuppressive agents, the incidence of PTLD appears to be increasing in solid organ transplant recipients [6 -9] . A dramatic increase in PTLD in Although only a small number of our patients (6) received pancreas transplant recipients at our institution followed the both high-dose OKT3 and ganciclovir/acyclovir, the use of initiation of antithymocyte globulin induction with OKT3 treatganciclovir/acyclovir was associated with lack of development ment for early rejection; development of this early onset PTLD of PTLD in all 6 patients (zero risk), whereas treatment with within 62 days of pancreas transplantation appears to be related high-dose OKT3 without ganciclovir/acyclovir prophylaxis into high cumulative doses of OKT3. Although primary EBV creased the risk of developing PTLD to 60% (3 of 5 patients).
infection has been noted to be an independent risk factor for However, the relatively small number of patients with PTLD PTLD in recipients of other solid organs [10] , the relative precluded the use of population-based statistical methods such lack of pretransplantation seronegativity for EBV in our patient as logistic regression analysis to confirm independent risk varipopulation precluded an analysis of this variable as a risk factor ables.
for our pancreas transplant recipients. A similar correlation between PTLD and high cumulative doses of OKT3 was previously noted in heart transplant recipiHistopathology, Treatment, and Outcome ents [7] , while the combination of OKT3 and antilymphocyte globulin appeared to predispose kidney transplant recipients to The diagnosis of PTLD was confirmed by immunohistochemical staining of atypical lymphocytes for the latent mem-PTLD [8] . Whether it is the cumulative dose itself, the number of days of administration of OKT3, or the mechanisms of brane protein-1 in all 4 cases, plus the demonstration of EBER RNA of EBV by in situ hybridization in 3 of the 4 cases.
OKT3 activity that actually cause B cell proliferation is unknown. It is also possible that the increased use of OKT3 may With use of the classification system of Knowles et al. [2] , the diagnosis for one of our patients was established as the least have been a marker for another process that could affect EBV replication and/or B cell proliferation, rather than a cause of aggressive form of PTLD (plasmacytic hyperplasia), which appeared to be confined to the pancreas allograft alone. Follow-PTLD. For example, early PTLD may have been associated with rejection or misdiagnosed as rejection during its developing removal of the pancreas and a decrease in overall immunosuppression, she was treated with high-dose intravenous ment, since infiltrating T cells can be seen with both conditions; either this association or the misdiagnosis might then have led acyclovir (the equivalent of 15 mg/kg q.d. for normal renal function) and was able to retain her kidney allograft; she reto additional immunosuppression with OKT3, which would result in correlation of a higher OKT3 dose with PTLD. mained disease-free 19 months following the diagnosis of PTLD.
Furthermore, in the current study, as in the previous studies that suggested a specific correlation of PTLD with OKT3 use Two of our patients were found to have an intermediate form of PTLD (polymorphic B cell hyperplasia/lymphoma) or dosage, it is likely that the cumulative degree of immunosuppression rather than the use of one or two specific agents is the that involved the transplanted pancreas and other organs (kidney, lymph nodes, gall bladder, and liver in one; kidney and underlying risk factor for PTLD. However, statistical analyses / 9c48$$mr24 02-05-98 21:41:37 cida UC: CID indicated that the cumulative dose of another potent immunolymphoma; intravenous immunoglobulin therapy was added for the two patients with polymorphic B cell hyperplasia/ suppressive agent (antithymocyte globulin) did not differ belymphoma, and IFN a therapy was added for the patient who tween the patients who developed PTLD and those who did had multiorgan involvement. The only patient with immunot (in both the pancreas and heart transplant [7] patients).
noblastic lymphoma was treated aggressively with chemotheraSimilarly, the use of FK506 was not significantly correlated peutic agents. All four of these patients have survived and with the development of PTLD in our patients, although this remained disease free a minimum of 18 months following the may have been because of the small number of patients who diagnosis of PTLD. developed PTLD and the sizable percentage of patients treated sequentially with both FK506 and cyclosporin A. Development of a method for quantifying the absolute degree of immunosup-
